GlassScriptPhysician profile
Carlos Remolina
NPI 1144398835
$68,971.51
in general payments reported to CMS, 2019-2025
24 companies · $5,812 in 2025
The $5,812 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $7,985 · 2021: $16K · 2022: $4,526 · 2023: $10K · 2024: $6,508 · 2025: $5,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $3,752 · Consulting Fee: $3,200 · Travel and Lodging: $3,058 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,600.00 |
| Food and Beverage | $3,751.90 |
| Consulting Fee | $3,200.00 |
| Travel and Lodging | $3,058.09 |
| Education | $178.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $64,448.23 | 2019-2025 | Ofev, Jascayd |
| Philips North America LLC | $1,886.14 | 2020-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (8874) Incourage |
| Astrazeneca Pharmaceuticals LP | $1,016.93 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $258.03 | 2019-2025 | Trelegy Ellipta |
| Insmed, INC. | $229.50 | 2023-2024 | Arikayce |
| Genzyme Corporation | $225.69 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $171.73 | 2019 | |
| Sanofi-Aventis U.S. LLC | $147.98 | 2022-2025 | |
| Pulmonx Corporation | $110.10 | 2020-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Regeneron Healthcare Solutions, INC. | $93.83 | 2019-2025 | Dupixent |
| Baxter Healthcare | $61.50 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Electromed, INC. | $51.70 | 2021-2025 | Smartvest |
| Ambu INC. | $39.56 | 2022 | |
| Sunovion Pharmaceuticals INC. | $38.41 | 2019-2020 | |
| United Therapeutics Corporation | $32.84 | 2024-2025 | Tyvaso, Tyvaso |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.57 | 2022-2025 | Tezspire |
| Covidien LP | $24.64 | 2019 | |
| Lilly USA, LLC | $17.38 | 2025 | Zepbound |
| Genentech USA, INC. | $15.24 | 2019 | |
| Mylan Specialty L.P. | $15.24 | 2021 | |
| Harmony Biosciences LLC | $14.66 | 2020 | |
| Mallinckrodt Hospital Products INC. | $14.40 | 2023 | Acthar |
| Axsome Therapeutics, INC. | $13.34 | 2023 | Sunosi |
| Merck Sharp & Dohme LLC | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Remolina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.